» Articles » PMID: 16842323

Comparison of Staging Systems to Predict Survival in Hepatocellular Carcinoma

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2006 Jul 18
PMID 16842323
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Some new staging systems in hepatocellular carcinoma (HCC) have been described in the last years. The aim of this study was to compare the survival-predicting capacity of some variables and the prognostic classifications.

Methods: Demographic, clinical, analytical variables and tumour characteristics were collected in a study including 115 patients with HCC. Predictors of survival were identified using the Kaplan-Meier test and the Cox model. Comparison between different staging systems was carried out.

Results: The 1-, 2- and 3-year estimated survival was 65%, 45% and 30%, respectively. Child-Pugh score and alpha-fetoprotein level greater than 400 UI/l were independent predictors of survival in the Cox model. Although all systems correctly differentiated between patients regarding survival (Kaplan-Meier, log rank < 0.05 for all), the Barcelona Clinic Liver Cancer (BCLC) showed a better discriminatory ability than the other evaluated scores. In addition, the independent homogenizing ability and stratification value of BCLC was better than that of other systems. On the contrary, model for end-stage liver disease (MELD) showed the worst results.

Conclusions: Child-Pugh score and alpha-fetoprotein levels were the only independent predictors of survival in patients with HCC. Child-Pugh score showed a better prediction value for survival when compared with MELD. BCLC is more accurate than the other prognostic models evaluated in this investigation.

Citing Articles

Inflammatory cytokines and alpha-fetoprotein concentrations for predicting survival in patients with hepatocellular carcinoma.

Han X, Gu Y, Li S, Chen M, Cai Q, Huang J Transl Cancer Res. 2022; 8(5):1680-1689.

PMID: 35116917 PMC: 8798832. DOI: 10.21037/tcr.2019.08.09.


Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma.

Pamecha V, Sasturkar S, Sinha P, Mahansaria S, Bharathy K, Kumar S Indian J Surg. 2017; 79(4):326-331.

PMID: 28827907 PMC: 5549045. DOI: 10.1007/s12262-016-1545-3.


Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.

Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M J Hepatocell Carcinoma. 2017; 4:93-103.

PMID: 28744453 PMC: 5513853. DOI: 10.2147/JHC.S106529.


Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.

Li J, Goh B, Chang P, Tan C World J Gastroenterol. 2017; 23(22):4054-4063.

PMID: 28652658 PMC: 5473124. DOI: 10.3748/wjg.v23.i22.4054.


Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N World J Hepatol. 2015; 7(20):2274-91.

PMID: 26380652 PMC: 4568488. DOI: 10.4254/wjh.v7.i20.2274.